Research programme: Mena protein isoforms therapeutics - MetaStat

Drug Profile

Research programme: Mena protein isoforms therapeutics - MetaStat

Alternative Names: Mena isoform proteins

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MetaStat Inc
  • Class Antibodies; Antineoplastics; Diagnostic agents; Monoclonal antibodies; Peptides; Small molecules
  • Mechanism of Action Actin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Aug 2017 MetaStat has four patent protection and allowance of claims in the US, and three international patents for the core Mena protein technology (MeStat website, August 2017)
  • 11 Aug 2017 Preclinical trials in Cancer in USA (unspecified route) (MetaStat pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top